CN102227435A - 丙型肝炎病毒抑制剂 - Google Patents

丙型肝炎病毒抑制剂 Download PDF

Info

Publication number
CN102227435A
CN102227435A CN2009801482121A CN200980148212A CN102227435A CN 102227435 A CN102227435 A CN 102227435A CN 2009801482121 A CN2009801482121 A CN 2009801482121A CN 200980148212 A CN200980148212 A CN 200980148212A CN 102227435 A CN102227435 A CN 102227435A
Authority
CN
China
Prior art keywords
mmol
solvent
alkyl
water
hcv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801482121A
Other languages
English (en)
Chinese (zh)
Inventor
S·希伯特
R·拉贾马尼
M·S·鲍谢尔
李荣缇
P·M·斯科拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102227435A publication Critical patent/CN102227435A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN2009801482121A 2008-09-29 2009-09-17 丙型肝炎病毒抑制剂 Pending CN102227435A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10090708P 2008-09-29 2008-09-29
US61/100907 2008-09-29
US12/559179 2009-09-14
US12/559,179 US20100080770A1 (en) 2008-09-29 2009-09-14 Hepatitis C Virus Inhibitors
PCT/US2009/057235 WO2010036551A1 (en) 2008-09-29 2009-09-17 Hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
CN102227435A true CN102227435A (zh) 2011-10-26

Family

ID=42057725

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801482121A Pending CN102227435A (zh) 2008-09-29 2009-09-17 丙型肝炎病毒抑制剂

Country Status (7)

Country Link
US (1) US20100080770A1 (enExample)
EP (1) EP2331552B1 (enExample)
JP (1) JP2012504126A (enExample)
CN (1) CN102227435A (enExample)
AR (1) AR073706A1 (enExample)
TW (1) TW201018477A (enExample)
WO (1) WO2010036551A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109020820A (zh) * 2017-06-08 2018-12-18 杭州惠诺医药科技有限公司 一种6-溴-2-氨基萘的制备方法

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011306A (es) * 2008-04-15 2010-11-09 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de la hepatitis c.
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) * 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8563505B2 (en) * 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
MX2011012155A (es) 2009-05-13 2012-02-28 Enanta Pharm Inc Compuestos macrociclicos como inhibidores del virus de hepatitis c.
CN105001302A (zh) * 2009-09-28 2015-10-28 英特穆恩公司 C型肝炎病毒复制的环肽抑制剂
WO2011049908A2 (en) * 2009-10-19 2011-04-28 Enanta Pharmaceuticals, Inc. Bismacrokyclic compounds as hepatitis c virus inhibitors
CN103649079B (zh) 2010-12-22 2016-11-16 Abbvie公司 丙型肝炎抑制剂及其用途
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CA2875718A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
NZ724503A (en) 2012-06-08 2017-12-22 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
BR112015007879A2 (pt) 2012-10-19 2017-07-04 Bristol Myers Squibb Co inibidores do vírus da hepatite c
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119061A2 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008051475A2 (en) * 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057209A1 (en) * 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057208A2 (en) * 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
CN101228181A (zh) * 2005-07-20 2008-07-23 默克公司 Hcv ns3蛋白酶抑制剂
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475255A3 (en) * 1990-09-12 1993-04-14 F. Hoffmann-La Roche Ag Process for the preparation of optically pure (s)-alpha-((tert-butylsulfonyl)methyl)hydro cinnamic acid
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
MY140680A (en) * 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
EP1629000B1 (en) * 2003-04-16 2009-02-18 Bristol-Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis c virus
WO2005090383A2 (en) * 2004-03-15 2005-09-29 Boehringer Ingelheim International, Gmbh Process for preparing macrocyclic dipeptides which are suitable for the treatment of hepatitis c viral infections
TW200738742A (en) * 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
US8268776B2 (en) * 2006-06-06 2012-09-18 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
US7635683B2 (en) * 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US7605126B2 (en) * 2006-08-11 2009-10-20 Enanta Pharmaceuticals, Inc. Acylaminoheteroaryl hepatitis C virus protease inhibitors
US7582605B2 (en) * 2006-08-11 2009-09-01 Enanta Pharmaceuticals, Inc. Phosphorus-containing hepatitis C serine protease inhibitors
US20080279821A1 (en) * 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119061A2 (en) * 2005-05-02 2006-11-09 Merck & Co., Inc. Hcv ns3 protease inhibitors
CN101228181A (zh) * 2005-07-20 2008-07-23 默克公司 Hcv ns3蛋白酶抑制剂
CN101233148A (zh) * 2005-08-01 2008-07-30 默克公司 作为hcv ns3蛋白酶抑制剂的大环肽
WO2008051475A2 (en) * 2006-10-24 2008-05-02 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057209A1 (en) * 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2008057208A2 (en) * 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109020820A (zh) * 2017-06-08 2018-12-18 杭州惠诺医药科技有限公司 一种6-溴-2-氨基萘的制备方法
CN109020820B (zh) * 2017-06-08 2021-06-25 杭州惠诺医药科技有限公司 一种6-溴-2-氨基萘的制备方法

Also Published As

Publication number Publication date
EP2331552A1 (en) 2011-06-15
JP2012504126A (ja) 2012-02-16
WO2010036551A1 (en) 2010-04-01
US20100080770A1 (en) 2010-04-01
TW201018477A (en) 2010-05-16
EP2331552B1 (en) 2013-02-27
AR073706A1 (es) 2010-11-24

Similar Documents

Publication Publication Date Title
CN102227435A (zh) 丙型肝炎病毒抑制剂
CN102307890B (zh) 丙型肝炎病毒抑制剂
CN102112486B (zh) 丙型肝炎病毒抑制剂
CN102317306B (zh) 丙型肝炎病毒抑制剂
JP5487209B2 (ja) Ｃ型肝炎ウイルス阻害剤
US8563505B2 (en) Hepatitis C virus inhibitors
CN103797024B (zh) 丙型肝炎病毒抑制剂
JP6078536B2 (ja) Ｃ型肝炎ウイルス阻害剤
CN102099359A (zh) 丙型肝炎病毒抑制剂
WO2009140475A1 (en) Hepatitis c virus inhibitors
TW201422620A (zh) Ｃ型肝炎病毒抑制劑
JP6342922B2 (ja) Ｃ型肝炎ウイルス阻害剤
CN101568543B (zh) 大环肽作为丙型肝炎病毒抑制剂
CN103732613B (zh) 丙型肝炎病毒抑制剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20111026